B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GABRA3

MOLECULAR TARGET

gamma-aminobutyric acid type A receptor subunit alpha3

UniProt: P34903NCBI Gene: 255613 compounds

GABRA3 (gamma-aminobutyric acid type A receptor subunit alpha3) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GABRA3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gamma-Aminobutyric Acid3.4731
2Pregnanolone2.208
3Bicuculline1.393
4Apigenin 5,7,4'-trihydroxy-flavone,1.102
5chrysin1.102
6Androsterone1.102
7Ciprofloxacin0.691
8Eszopiclone0.691
9Etiocholanolone0.691
10Etomidate Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or0.691
11Ondansetron0.691
12Picrotoxin0.691
13Triiodothyronine0.691

About GABRA3 as a Drug Target

GABRA3 (gamma-aminobutyric acid type A receptor subunit alpha3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented GABRA3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GABRA3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.